Research programme: RNA interference-based therapeutics - Dharmacon/University of Massachusetts Medical School
Latest Information Update: 02 May 2007
At a glance
- Originator Dharmacon; University of Massachusetts Medical School
- Class Small interfering RNA
- Mechanism of Action Genetic transcription inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus; Obesity
Most Recent Events
- 06 Apr 2004 Dharmacon has been acquired by Fisher Scientific International
- 16 Jan 2004 Preclinical trials in Diabetes mellitus in USA (unspecified route)
- 16 Jan 2004 Preclinical trials in Obesity in USA (unspecified route)